Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tegoprazan BID PK/PD in Healthy Subjects
NCT04587011Phase 1Unknown
- Sponsor
- HK inno.N Corporation
- Start
- Sep 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tegoprazan in gastroesophageal reflux disease (GERD) (4 arms), sponsored by HK inno.N Corporation. Primary endpoint: Pharmacokinetics Evaluation up to 24 hours. Status: unknown.
02
Drugs
tegoprazan
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT04587011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04587011.